Enterprise Value to EBITDA Ratio: Y-mAbs Therapeutics (YMAB)
The price history of Y-mAbs Therapeutics (YMAB) demonstrates an EV/EBITDA ratio of . The business relies on the commercialization of targeted antibodies to combat rare forms of malignant tumors, utilizing radioimmunotherapy to destroy metastases. Y-mAbs Therapeutics (YMAB) possesses a powerful scientific and technical resource in the field of pediatric oncology, while management is currently optimizing expenses and updating the commercial plan to regain shareholder confidence.
YMAB (ymabs.com): analytical breakdowns and indicator data
- current price and projected stock value:
- company stock exchange capitalization indicators:
- business book valuation details:
- issuer credit burden and liquidity indicators:
Total Debt to Equity Ratio Y-mAbs Therapeutics|YMAB - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio Y-mAbs Therapeutics, Inc.|YMAB - Company Total Indebtedness|Debt to Book Capitalization Ratio Y-mAbs Corp|YMAB - Company Long-Term Liabilities|Company Short-Term Debts Y-mAbs Therapeutics|Quick Ratio ymabs.com
- business earnings and investment ratios data:
YMAB - Company Net Income|Expected Profit Y-mAbs Therapeutics|YMAB - Business Payback Period|Projected Price to Earnings Y-mAbs Therapeutics|YMAB - Growth-Adjusted Payback Ratio|Enterprise Value to EBITDA Ratio Y-mAbs Corp|YMAB - Company profit before taxes, interest and amortization|Net earnings per share (EPS TTM) Y-mAbs Therapeutics|YMAB - Earnings per share for the trailing year|Quarterly EPS earnings growth ymabs.com|YMAB - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Y-mAbs Therapeutics
Basic company analysis:YMAB (YmAbs)
The development of unique antibodies to combat pediatric brain tumors creates a high barrier to entry for Y-mAbs Therapeutics (YMAB). The company's dynamic EV/EBITDA ratio reflects the enterprise value relative to its operating profit. This multiple measures the payback period of assets, allowing for an assessment of model sustainability amid significant capital expenditures. Low indicator values confirm either an undervalued asset or the risk of capital degradation.
Competitors of Y-mAbs Therapeutics (YMAB)
EV/EBITDA Multiple ONC (BeiGene Corp)|HALO - Enterprise Value to EBITDA Ratio|RVMD: Enterprise Value to EBITDA Ratio|AAPG - EV/EBITDA Multiple|CG Oncology (CGON) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|UroGen Pharma Ltd - Business Value to Operating Income Before Depreciation|BCAX (Bicara Bio) - EV/EBITDA Multiple|Company Value to EBITDA Personalis Genomics PSNL|Enterprise Value to EBITDA Ratio ERAS (Erasca, Inc.)|DCTH - Company Value to EBITDA|Aura Biosciences - Enterprise Value to EBITDA Ratio|Enterprise Value to EBITDA Multiple Candel Therapeutics Inc.|ARAY - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|SELLAS Life Sciences (SLS) - Enterprise Value to EBITDA Ratio|ACTU: EV/EBITDA Multiple|citiusonc.com (CTOR) - EV/EBITDA Multiple|HURA (TuHURA Biosciences Inc.) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization TARA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Fate Therapeutics Corp (FATE)|Total Company Value to Operating Income Before Depreciation Ratio aadibio.com|TScan Therapeutics, Inc. - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation CSBR|XBIT: Enterprise Value to EBITDA Ratio|CEL-SCI Corporation - Enterprise Value to Operating Income Before Depreciation Ratio|OSTX: EV/EBITDA Multiple|Radiopharm Theranostics Ltd - Business Value to Operating Income Before Depreciation|ARTV (Artiva Biotherapeutics Inc.) - EV/EBITDA Multiple|Company Value to EBITDA Adlai Nortye Limited ANL|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Veru (VERU)|TPST (Tempest Therapeutics Inc) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple XLO (Xilio Therapeutics)|EV/EBITDA Multiple Renovaro Biosciences RENB|MURA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio KAPA|OKUR: EV/EBITDA Multiple|Company Value to EBITDA CytoMed Therapeutics Limited (GDTC)|Enterprise Value to EBITDA Ratio CRIS|EV/EBITDA Multiple Apollomics Corp|Enterprise Value to EBITDA Ratio THAR (Tharimmune, Inc.)|Enterprise Value to Operating Income Before Depreciation Ratio ADVB|EV/EBITDA Multiple GNPX (Genprex)|Total Company Value to Operating Income Before Depreciation Ratio Calidi Biotherapeutics Inc. (CLDI)|Sunshine Biopharma - EV/EBITDA Multiple|Xenetic Biosciences (XBIO) - Enterprise Value to EBITDA Ratio|Salarius Pharmaceuticals (SLRX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|PPBT - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio AONC|Company Value to EBITDA BeiGene Ltd. BGNE|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Checkpoint Therapeutics, Inc (CKPT)|Enterprise Value to EBITDA Ratio Elevation Oncology Inc. ELEV|EV/EBITDA Multiple ICAD (iCAD)|EV/EBITDA Multiple Ikena Oncology Inc. IKNA|Notable Labs - EV/EBITDA Multiple|VIRX: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|MOR: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio NAYA Biosciences Corp|AAPGV (Ascentage Pharma Group) - EV/EBITDA Multiple
